ClinicalTrials.gg
Not yet recruitingNCT07656779Updated Jun 18, 2026

Human Mass Balance Study of [¹⁴C]HRS-1893

A Phase 1 interventional study of [14C]HRS-1893 in Cardiomyopathies, sponsored by Shandong Suncadia Medicine Co., Ltd.. Not yet recruiting at 1 site in China. Open to male participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-06-18.

Sponsored by Shandong Suncadia Medicine Co., Ltd. (part of Jiangsu HengRui Medicine Co., Ltd.) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Jul 2026, 4 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
6
Allocation
Not applicable
Ages
18 Years to 45 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 25 studies in Cardiomyopathies with a site in China — 12 open to participants now, 12 under way, 1 of them phase 3. Cardiomyopathies · China.

Planned enrollment
13th of 13
6 · median 96
Started
2026
with 2 others
Phase 1
4 of 25
1 open now
Primary completion
2026-07
later than 3 of 11 live
Registered
24th of 25
by date
Lead sponsor
3 of 25
Shandong Suncadia Medicine Co., Ltd.

Among the 25 studies in Cardiomyopathies with a site in China, this one is the 13th largest by planned enrollment of the 13 interventional ones that give a count, is one of 3 that started in 2026, is one of 4 in phase 1, reaches primary completion later than 3 of the 11 other live ones, and was the 24th registered.

Cardiomyopathies

553 studies on the registry are indexed under Cardiomyopathies; 151 are open to participants now.

Browse Cardiomyopathies studies →

Open to participants now

12 of the 25 studies in Cardiomyopathies with a site in China are open now. Recruiting first, the newest first:

6 more — sign in →

All 12 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 115 Cardiomyopathies studies recruiting now, 70 (61%) set no upper age limit and 17 (15%) stop at 75 or younger; 35 take children under 18; 22 take healthy volunteers.

This study: 18 Years to 45 Years · male · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 25 studies in Cardiomyopathies with a site in China, or all of them as a file.
02

Study summary

HRS-1893-107 is a Phase 1, single-center, non-randomized, open-label, single-dose study designed to investigate the mass balance, metabolism, and pharmacokinetics of [14C]HRS-1893. The study aims to quantify the radioactive recovery rate, determine the primary excretion pathways, evaluate the whole blood-to-plasma radioactivity ratio, identify major metabolites, and characterize the pharmacokinetic (PK) profile of HRS-1893 and its metabolites. Safety and tolerability will be monitored throughout the trial.

03

Conditions studied

  • Cardiomyopathies

Browse trials for

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age range: 18 - 45 years old (inclusive of the boundaries, based on the date of signing the form). Healthy male.
  2. (BMI) ranging from 19 to 26 kg/m2 (including the boundary values), with a weight of ≥ 50.0 kg.
  3. After comprehensive physical examinations (including vital signs, physical examinations, etc.) and laboratory tests (such as blood routine, blood biochemistry, coagulation function, urine routine, fecal routine + occult blood, thyroid function), as well as abdominal B-ultrasound and chest anteroposterior X-ray films, no abnormalities were found (, AST, total , direct bilirubin, creatine kinase must be \< 1.5 times the reference value, (eGFR) > 90 mL/(min·1.73 m2)), or the researchers judged that there were minor abnormalities that did not affect the participants' enrollment (such as hemangioma, cyst, calcification focus, nodules, etc.). Among them, abdominal B-ultrasound and chest anteroposterior X-ray films can accept the abdominal B-ultrasound or abdominal CT that can be traced within 6 months before administration, and the results of chest anteroposterior X-ray films or chest CT.
  4. The 12-lead shows no clinically significant abnormalities (among which Fridericia (QTcF) must be \< 450 ms).
  5. Understand the research procedures and methods, voluntarily participate in this trial, and sign the informed consent form in person.

Exclusion criteria

Exclusion Criteria:

  1. Systolic blood pressure (SBP) during the screening period or baseline period: SBP ≥ 140 mmHg or \< 90 mmHg; Diastolic blood pressure (DBP): DBP ≥ 90 mmHg or \< 60 mmHg, and the clinical doctor determines that it has clinical significance.
  2. During the screening period, any one of the following infectious disease screenings - surface antigen, antibody, syphilis antibody, or antibody - showing any abnormal result and judged by the researcher to have clinical significance will be included.
  3. There is a history of syncope in the past.
  4. Those who have a history of allergies to drugs, foods, or the environment, or who are allergic to the test drug or any of its components.
  5. Within one month prior to taking the research drug, any prescription drugs, over-the-counter drugs, or herbal medicines were taken; those whose drug half-life was within five half-lives at the time of screening; and those who plan to take non-research trial drugs during the trial period.
  6. Select those who smoked an average of more than 5 cigarettes per day over the past 4 weeks; those who consumed an average of more than 15 grams of alcohol per day in a week (15 grams of alcohol is equivalent to 450 mL of beer or 150 mL of wine or 50 mL of low-alcohol liquor); or those whose alcohol breath test result was greater than 0 mg/100 mL during the screening period; or those who refrained from smoking, drinking alcohol and consuming caffeinated foods or beverages during the screening period and the test period, and had special dietary requirements that they could not comply with the unified diet.
  7. Habitual constipation or diarrhea.
  8. Those with a history of drug use or substance abuse; or those who tested positive for drug abuse in the screening urine test during the selection process.
  9. Those who habitually consume grapefruit juice or excessive amounts of tea, coffee and/or caffeinated beverages, or those who are unable to quit during the trial period.
  10. Those who have a history of fainting during blood collection or blood transfusion, or who have difficulty in blood collection or cannot tolerate venipuncture for blood collection.
  11. Screen those who have participated in any clinical trials of drugs or medical devices within the past three months (the definition of participation in clinical trials is based on the participants receiving treatment with the trial drugs or medical devices).
  12. Those who received the vaccine within the previous 1 month or during the trial period or within 1 month after administration.
  13. Those who had experienced blood loss or blood donation of 400 mL within the past 3 months, or those who received blood transfusion within the past 1 month will be selected.
  14. Staff members of the research center or other individuals directly involved in the implementation of the plan.
  15. The researchers believe that there are other circumstances that make the participants unsuitable for this trial, such as those that might increase the risk of the trial, affect the participants' compliance with the protocol, or cause physical or psychological conditions that prevent them from completing the trial.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
6 participants (estimated)

Study arms

  • Experimental
    [14C]HRS-1893 Group

    \[14C\]HRS-1893.

    Drug: [14C]HRS-1893

Interventions

06

What researchers measure

Primary outcomes

  1. Total radioactivity ratio of whole blood/plasma

    Time frame: 0 to anticipated 11 days.

  2. Time to reach maximum concentration (Tmax)

    Time frame: 0 to anticipated 11 days.

  3. Maximum concentration (Cmax)

    Time frame: 0 to anticipated 11 days.

  4. Area under the plasma concentration-time curve from Time 0 to the last quantifiable time point (AUC0-t)

    Time frame: 0 to anticipated 11 days.

  5. Area under the plasma concentration-time curve from Time 0 to infinity (AUC0-∞)

    Time frame: 0 to anticipated 11 days.

  6. Half-life (t1/2)

    Time frame: 0 to anticipated 11 days.

  7. Apparent clearance (CL/F)

    Time frame: 0 to anticipated 11 days.

  8. Apparent volume of distribution (V/F)

    Time frame: 0 to anticipated 11 days.

  9. Percentage of parent drug and its metabolites in plasma as a percentage of total radioactive exposure (%AUC)

    Time frame: 0 to anticipated 11 days.

  10. Percentage of parent drug and its metabolites in urine and feces as a percentage of administered dose (%Dose)

    Time frame: 0 to anticipated 11 days.

  11. Total radioactivity ratio for blood/plasma

    Time frame: 0 to anticipated 11 days.

  12. The cumulative recovery amount and recovery rate of total radioactive substances in urine and feces

    Time frame: 0 to anticipated 11 days.

Secondary outcomes

  1. Safety and tolerability as measured by incidence of adverse events (AEs) and serious AEs

    Time frame: 0 to anticipated 11 days.

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jun 2026; primary completion for Jul 2026, 1 month later.

Of 16 phase 1 interventional studies under Cardiomyopathies, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 58. This study's planned 1 month is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 15, 2026
First posted
Jun 18, 2026
StartEst.
Jun 2026
Primary completionEst.
Jul 2026
CompletionEst.
Jul 2026
Last update
Jun 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 18, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07656779
Responsible party
Sponsor
First posted
Jun 18, 2026
Start date
Jun 2026 (estimated)
Primary completion
Jul 2026 (estimated)
Completion
Jul 2026 (estimated)
Last update
Jun 18, 2026

Study contacts

Wenzheng Xiong
Contact
wenzheng.xiong.wx10@hengrui.com
+86-0518-82342973
Jing He
Contact
jing.he@hengrui.com
+86-0518-82342973

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: HRS-1893

Start the discussion